Sentinel Lymph Node Biopsy in High-Grade Endometrial Cancer
Sentinel lymph node (SLN) biopsy should be performed for surgical staging in all patients with high-grade endometrial carcinoma and presumed uterus-confined disease, as it provides accurate nodal assessment with 92-96% sensitivity while avoiding the morbidity of complete lymphadenectomy.
Primary Recommendation
The most recent 2025 ESGO-ESTRO-ESP guidelines explicitly state that sentinel lymph node biopsy should be done for staging purposes in all patients with presumed uterus-confined disease 1. This applies equally to high-grade histologies (serous, clear cell, carcinosarcoma, grade 3 endometrioid). The NCCN 2023 guidelines similarly endorse SLN mapping as the preferred alternative to full lymphadenectomy in apparent uterine-confined disease 2.
Technical Approach
Preferred Detection Method
- Indocyanine green (ICG) with cervical injection is the preferred detection technique 1
- Tracer re-injection is an option if SLNs are not visualized initially 1
- Detection rates with ICG range from 89-91% per patient 2, 3
Critical Surgical Algorithm
If SLNs are not detected on either pelvic side:
- Perform side-specific systematic lymphadenectomy for high-risk patients 1
- This backup approach reduces the false-negative rate from 8% to 4.3% 4
- Can be considered in presumed intermediate-risk patients 1
Diagnostic Accuracy in High-Grade Disease
The evidence strongly supports SLN mapping specifically in high-grade endometrial cancer:
- Sensitivity: 92-96% across multiple studies 2, 4, 3
- False-negative rate: 4-8% (comparable to breast cancer and melanoma) 4, 3
- Negative predictive value: 97-99% 2, 3
- The SENTOR trial demonstrated 96% sensitivity (95% CI: 81-100%) in 156 patients with intermediate and high-grade disease 2
A 2021 systematic review and meta-analysis of 429 patients with high-grade histology confirmed these performance characteristics, concluding that SLN biopsy can replace complete lymphadenectomy as standard of care 3.
Ultrastaging Requirements
All sentinel lymph nodes must be subjected to ultrastaging 1. This involves:
- Serial sectioning at multiple levels (at least 2 additional levels, 50-250µ apart) 1
- Combined H&E staining and immunohistochemistry 2
- Ultrastaging detects metastases in 5-15% of patients that would be missed by standard sectioning 2
- This leads to upstaging and altered adjuvant therapy recommendations in a significant proportion of cases 2
Clinical Impact on Outcomes
Survival Data
- Multi-institutional retrospective studies show no difference in survival outcomes between SLN mapping alone versus SLN mapping with complete lymphadenectomy in high-risk endometrial cancer 2
- Recurrence-free survival at 50 months was 84.7% in patients with detected SLNs, with no difference between positive and negative SLN groups 2
Detection Advantage
- SLN mapping with ultrastaging detects 3-fold more metastatic nodes compared to standard lymphadenectomy (30.3% vs 14.7%, p<0.001) 2
- This improved detection allows for more appropriate adjuvant therapy prescription
Important Caveats
When NOT to Perform SLN Mapping
- Apparent distant metastatic disease on imaging or surgical exploration - node removal for staging is unnecessary as it won't change management 2
- Gross extrauterine disease at time of surgery 4
Institutional Requirements
- SLN mapping should only be performed at institutions with expertise in this procedure 2
- Requires availability of near-infrared imaging for ICG detection
- Pathology expertise in ultrastaging protocols is essential
Low-Volume Metastases
The clinical significance of isolated tumor cells (ITCs) remains unclear 2. Current evidence suggests:
- ITCs are designated as pN0(i+) and don't affect overall staging 2
- Patients with ITCs have similar 3-year recurrence-free survival (95.5%) as those with negative nodes 2
- It remains uncertain whether patients with ITCs benefit from adjuvant therapy 2
- Only macrometastases showed significantly worse outcomes (71% RFS at 3 years, p<0.001) 2
Integration with Molecular Classification
The 2025 guidelines emphasize that molecular classification is needed for proper risk group allocation, particularly in high-grade histologies 1. SLN mapping provides the surgical staging component, while molecular profiling augments treatment decisions in patients with negative nodes and intermediate-risk uterine factors 5.
Practical Implementation
The standard surgical procedure for stage I-II high-grade endometrial cancer includes 1:
- Total hysterectomy with bilateral salpingo-oophorectomy
- SLN mapping with ICG cervical injection
- Side-specific lymphadenectomy if SLN not detected
- Infracolic omentectomy for serous, carcinosarcoma, and undifferentiated histologies
- Ultrastaging of all retrieved SLNs
This approach balances accurate staging with reduced surgical morbidity, particularly lower extremity lymphedema, while maintaining oncologic safety 5.